Version



Date of last issue: 13.09.2019

Olmesartan Formulation

Revision Date:

SDS Number:

Version 2.3	Revision Date: 10.10.2020	SDS Number: 717985-00010	Date of first issue: 13.09.2019 Date of first issue: 01.06.2016
SECTION	I 1. PRODUCT AND CO	OMPANY IDENTIFIC	CATION
Prod	uct name	: Olmesartan F	ormulation
Man	ufacturer or supplier's	details	
Com Addr	pany name of supplier ess		o. e Septiembre No. 301 chimilco Mexico 16090
Eme	phone rgency telephone ail address	: 52 55 572844 : 215-631-6999	44
Reco	ommended use of the	chemical and restr	ictions on use
Reco	ommended use	: Pharmaceutic	al
SECTION	2. HAZARDS IDENTIF	ICATION	
GHS	Classification		
Repr	oductive toxicity	: Category 1A	
GHS	label elements		
Haza	ard pictograms		
Sign	al Word	: Danger	
Haza	ard Statements	: H360D May d	amage the unborn child.
Prec	autionary Statements	P202 Do not h and understoo P280 Wear pr face protectio Response:	rotective gloves/ protective clothing/ eye protection/
		attention. Storage:	
		P405 Store lo	cked up.
		Disposal: P501 Dispose posal plant.	of contents/ container to an approved waste dis-

Other hazards

Dust contact with the eyes can lead to mechanical irritation. Contact with dust can cause mechanical irritation or drying of the skin. May form explosive dust-air mixture during processing, handling or other means.



Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.3	10.10.2020	717985-00010	Date of first issue: 01.06.2016

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Component	ts
-----------	----

-		
Chemical name	CAS-No.	Concentration (% w/w)
Olmesartan	144689-63-4	>= 5 -< 10
Cellulose	9004-34-6	>= 5 -< 10
Collaiobe	0001010	2-0 110

SECTION 4. FIRST AID MEASURES

General advice	:	In the case of accident or if you feel unwell, seek medical advice immediately. When symptoms persist or in all cases of doubt seek medical advice.
If inhaled	:	If inhaled, remove to fresh air. Get medical attention.
In case of skin contact	:	In case of contact, immediately flush skin with soap and plenty of water. Remove contaminated clothing and shoes. Get medical attention. Wash clothing before reuse. Thoroughly clean shoes before reuse.
In case of eye contact	:	If in eyes, rinse well with water. Get medical attention if irritation develops and persists.
If swallowed	:	If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.
Most important symptoms and effects, both acute and delayed	:	
Protection of first-aiders	:	
Notes to physician	:	Treat symptomatically and supportively.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media	:	Water spray Alcohol-resistant foam Carbon dioxide (CO2) Dry chemical
Unsuitable extinguishing media	:	None known.
Specific hazards during fire fighting	:	Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard. Exposure to combustion products may be a hazard to health.
Hazardous combustion prod- ucts	:	Carbon oxides



Olmesartan Formulation

Versior 2.3	Revision Date: 10.10.2020		0S Number: 7985-00010	Date of last issue: 13.09.2019 Date of first issue: 01.06.2016
od Sp	Specific extinguishing meth- ods Special protective equipment for fire-fighters		Use extinguishing measures that are appropriate to local of cumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to so. Evacuate area. In the event of fire, wear self-contained breathing apparate Use personal protective equipment.	
SECTI	ON 6. ACCIDENTAL RELE	AS	EMEASURES	
tiv	rsonal precautions, protec- e equipment and emer- ncy procedures	:		ective equipment. ing advice (see section 7) and personal ent recommendations (see section 8).
Er	Environmental precautions		Retain and dispos	akage or spillage if safe to do so. e of contaminated wash water. should be advised if significant spillages
	Methods and materials for containment and cleaning up		container for disper Avoid dispersal of with compressed Dust deposits sho surfaces, as these released into the a Local or national r disposal of this ma employed in the c determine which r Sections 13 and 1	dust in the air (i.e., clearing dust surfaces

SECTION 7. HANDLING AND STORAGE

Technical measures	 Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
Local/Total ventilation	 If sufficient ventilation is unavailable, use with local exhaust ventilation.
Advice on safe handling	 Do not get on skin or clothing. Do not breathe dust. Do not swallow. Avoid contact with eyes. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition.



Olmesartan Formulation

Version 2.3	Revision Date: 10.10.2020	SDS Number: 717985-00010	Date of last issue: 13.09.2019 Date of first issue: 01.06.2016
Hygiene measures		 Take care to p environment. If exposure to flushing system place. When using d Wash contam The effective of engineering co appropriate de industrial hygi 	onary measures against static discharges. brevent spills, waste and minimize release to the chemical is likely during typical use, provide eye ms and safety showers close to the working o not eat, drink or smoke. inated clothing before re-use. operation of a facility should include review of ontrols, proper personal protective equipment, egowning and decontamination procedures, ene monitoring, medical surveillance and the strative controls.
Conditions for safe storage		Store locked u Keep tightly cl	osed.
Materials to avoid			

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis
Olmesartan	144689-63-4	TWA	30 µg/m3 (OEB 3)	Internal
		Wipe limit	300 µg/100 cm ²	Internal
Cellulose	9004-34-6	VLE-PPT	10 mg/m ³	NOM-010-
				STPS-2014
		TWA	10 mg/m ³	ACGIH

 Engineering measures All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices). Minimize open handling.

Personal protective equipment

Respiratory protection Filter type Hand protection		If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Particulates type
Material	:	Chemical-resistant gloves



Olmesartan Formulation

Version 2.3	Revision Date: 10.10.2020	SDS Number: 717985-00010	Date of last issue: 13.09.2019 Date of first issue: 01.06.2016
	emarks protection	If the work en mists or aeros Wear a facest	ble gloving. lasses with side shields or goggles. vironment or activity involves dusty conditions, sols, wear the appropriate goggles. hield or other full face protection if there is a irect contact to the face with dusts, mists, or
Skin a	and body protection	: Work uniform Additional boo task being per disposable su	or laboratory coat. ly garments should be used based upon the formed (e.g., sleevelets, apron, gauntlets, its) to avoid exposed skin surfaces. ite degowning techniques to remove potentially clothing.

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	powder
Color	:	No data available
Odor	:	No data available
Odor Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	Not applicable
Evaporation rate	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Vapor pressure	:	No data available
Relative vapor density	:	No data available
Relative density	:	No data available
Density	:	No data available
Solubility(ies)		



Olmesartan Formulation

Versi 2.3	ion Revision Date: 10.10.2020	SDS Number:Date of last issue717985-00010Date of first issue	
	Water solubility	: No data available	
	Partition coefficient: n-	: No data available	
	Autoignition temperature	: No data available	
	Decomposition temperature	: No data available	
,	Viscosity Viscosity, kinematic	: No data available	
	Explosive properties	: Not explosive	
	Oxidizing properties	: The substance or mixture is not clas	ssified as oxidizing.
	Molecular weight	: No data available	
	Particle size	: No data available	

SECTION 10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	 Not classified as a reactivity hazard. Stable under normal conditions. May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents. 	
Conditions to avoid	: Heat, flames and sparks. Avoid dust formation.	
Incompatible materials Hazardous decomposition products	 Oxidizing agents No hazardous decomposition products are known. 	

SECTION 11. TOXICOLOGICAL INFORMATION

Information on	likely routes	of exposure
----------------	---------------	-------------

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity	:	Acute toxicity estimate: > 5,000 mg/kg
		Method: Calculation method

Components:

Olmesartan:

Acute oral toxicity

: LD50 (Rat): > 2,000 mg/kg



3	Revision Date: 10.10.2020		OS Number: 7985-00010	Date of last issue: 13.09.2019 Date of first issue: 01.06.2016
			LD50 (Mouse):	> 2,000 mg/kg
			LD50 (Dog): > ²	1,500 mg/kg
Acute	inhalation toxicity	:	Remarks: No da	ata available
Acute	e dermal toxicity	:	Remarks: No da	ata available
Cellu	lose:			
Acute	e oral toxicity	:	LD50 (Rat): > 5	,000 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): > 5 Exposure time: Test atmosphere	4 h
Acute	e dermal toxicity	:	LD50 (Rabbit):	> 2,000 mg/kg
Not cl	corrosion/irritation lassified based on ava	ailable	information.	
-	ponents:			
Olme Rema	e sartan: arks	:	No data availab	le
Not cl	ous eye damage/eye i lassified based on ava ponents:			
Not cl	lassified based on ava			
Not cl <u>Com</u>	lassified based on ava ponents: sartan: ies lt			ritation
Not cl <u>Comp</u> Olme Speci Resul Metho	lassified based on ava ponents: sartan: ies lt	ailable : :	information. Rabbit Moderate eye ii Draize Test	ritation
Not cl Comp Olme Speci Resul Metho Resp	lassified based on ava ponents: esartan: ies lt od	ailable : :	information. Rabbit Moderate eye ii Draize Test	ritation
Not cl Comp Olme Speci Resul Metho Resp Skin	lassified based on ava ponents: esartan: ies It od iratory or skin sensi	ailable : : tizatic	information. Rabbit Moderate eye ii Draize Test	ritation
Not cl Comp Olme Speci Resul Metho Resp Skin s Not cl Resp	lassified based on ava ponents: esartan: ies lt od iratory or skin sensi sensitization	ailable : tizatic ailable	information. Rabbit Moderate eye ii Draize Test n information.	ritation
Not cl Comp Olme Speci Resul Metho Resp Skin Not cl Resp Not cl	lassified based on ava ponents: esartan: ies lt od iratory or skin sensi sensitization lassified based on ava iratory sensitization	ailable : tizatic ailable	information. Rabbit Moderate eye ii Draize Test n information.	ritation
Not cl Comp Olme Speci Resul Metho Resp Skin Not cl Resp Not cl Comp	lassified based on ava ponents: esartan: ies it od iratory or skin sensi sensitization lassified based on ava iratory sensitization lassified based on ava	ailable : tizatic ailable	information. Rabbit Moderate eye ii Draize Test n information.	ritation



rsion	Revision Date: 10.10.2020	SDS N 717985	umber: 5-00010	Date of last issue: 13.09.2019 Date of first issue: 01.06.2016
<u>Com</u>	<u>oonents:</u>			
Olme	sartan:			
Geno	toxicity in vitro		st Type: Bac sult: negativ	cterial reverse mutation assay (AMES) re
			st Type: Mu sult: negativ	tagenicity (in vitro mammalian cytogenetic tes e
		Tes		romosome aberration test in vitro Chinese hamster lung cells
			st Type: Mo sult: negativ	use Lymphoma re
Geno	toxicity in vivo	Spe Cel App	at Type: Mice ecies: Mous I type: Bone blication Ro sult: negativ	e marrow ute: Oral
	cell mutagenicity - ssment		ight of evide mutagen.	ence does not support classification as a ger
Cellu	lose:			
Geno	toxicity in vitro		st Type: Bac sult: negativ	cterial reverse mutation assay (AMES) re
			st Type: In v sult: negativ	ritro mammalian cell gene mutation test re
Geno	toxicity in vivo	cyto Spe App	ogenetic as ecies: Mous	e ute: Ingestion
	nogenicity assified based on ava	ilable infor	mation.	
	oonents:			
Olme	sartan:			
	cation Route sure time			

Result	:	negative
Species Application Route Exposure time Result	:	Mouse Oral 6 Months negative



Vers 2.3	sion	Revision Date: 10.10.2020		9S Number: 7985-00010	Date of last issue: 13.09.2019 Date of first issue: 01.06.2016
			:	Rat Ingestion 72 weeks negative	
	-	ductive toxicity amage the unborn child			
	Compo	onents:			
	Olmes	artan:			
	Effects	on fertility	:	Test Type: Fertility Species: Rat Application Route Fertility: NOAEL: Result: No effects	: Oral 1,000 mg/kg body weight
	Effects	on fetal development	:	Symptoms: Malfor weight	: Oral cam per kilogram genic effects. opment : Oral per kilogram genic effects.
	Reproc sessme	ductive toxicity - As- ent	:	Positive evidence human epidemiolo	of adverse effects on development from ogical studies.
	Cellulo	ose:			
	Effects	on fertility	:	Test Type: One-g Species: Rat Application Route Result: negative	eneration reproduction toxicity study : Ingestion
	Effects	on fetal development	:	Test Type: Fertility Species: Rat Application Route Result: negative	/early embryonic development



rsion 3	Revision Date: 10.10.2020	SDS Number: 717985-00010	Date of last issue: 13.09.2019 Date of first issue: 01.06.2016
STOT	-single exposure		
Not cl	assified based on ava	ailable information.	
	-repeated exposure		
Not cl	assified based on ava	ailable information.	
Repe	ated dose toxicity		
<u>Comp</u>	oonents:		
Olme	sartan:		
Speci		: Rat	
NOAE Applic	L cation Route	: 2,000 mg/kg : Oral	
	sure time	: 24 Months	
Rema	ırks	: No significant a	adverse effects were reported
Cellul	lose:		
Speci	es	: Rat	
NOAE		: >= 9,000 mg/k	g
	cation Route sure time	: Ingestion : 90 Days	
Not cl	ation toxicity assified based on ava rience with human e		
Not cl Exper Comp Olme	assified based on ava rience with human e ponents: sartan:	exposure	
Not cl Exper Comp Olme Eye c	assified based on ava rience with human e <u>ponents:</u> sartan: ontact	exposure : Symptoms: Ey	
Not cl Exper Comp Olme	assified based on ava rience with human e <u>ponents:</u> sartan: ontact	: Symptoms: Ey : Symptoms: hy Remarks: May	potension cause harm to the unborn child.
Not cl Exper Comp Olme Eye c	assified based on ava rience with human e <u>ponents:</u> sartan: ontact	exposure : Symptoms: Ey : Symptoms: hy	potension cause harm to the unborn child.
Not cl Exper Comp Olme Eye cl Ingest	assified based on ava rience with human e <u>ponents:</u> sartan: ontact	 Symptoms: Ey Symptoms: hy Remarks: May Based on Hum 	potension cause harm to the unborn child.
Not cl Exper Comp Olme Eye cl Ingest	assified based on ava rience with human e <u>ponents:</u> sartan: ontact tion	 Symptoms: Ey Symptoms: hy Remarks: May Based on Hum 	potension cause harm to the unborn child.
Not cl Exper Comp Olme Eye cl Ingest	assified based on ava rience with human e <u>conents:</u> sartan: ontact tion 12. ECOLOGICAL IN	 Symptoms: Ey Symptoms: hy Remarks: May Based on Hum 	potension cause harm to the unborn child.
Not cl Exper Comp Olme Eye cl Ingest	assified based on ava rience with human e <u>ponents:</u> sartan: ontact tion 12. ECOLOGICAL IN pxicity ponents:	 Symptoms: Ey Symptoms: hy Remarks: May Based on Hum 	potension cause harm to the unborn child.
Not cl Exper Comp Olme Eye cl Ingest CTION Ecoto Comp Cellul	assified based on ava rience with human e <u>ponents:</u> sartan: ontact tion 12. ECOLOGICAL IN pxicity ponents:	 Symptoms: Ey Symptoms: hy Remarks: May Based on Hum NFORMATION LC50 (Oryzias Exposure time 	potension cause harm to the unborn child. han Evidence latipes (Japanese medaka)): > 100 mg/l
Not cl Exper Comp Olme Eye cl Ingest CTION Ecoto Comp Cellul Toxici	assified based on ava rience with human e <u>ponents:</u> sartan: ontact tion 12. ECOLOGICAL IN pxicity ponents: lose:	 Symptoms: Ey Symptoms: hy Remarks: May Based on Hum NFORMATION LC50 (Oryzias Exposure time Remarks: Base 	potension cause harm to the unborn child. han Evidence latipes (Japanese medaka)): > 100 mg/l : 48 h
Not cl Exper Comp Olme: Eye cl Ingest CTION Ecoto Comp Cellul Toxici	assified based on ava rience with human e <u>ponents:</u> sartan: ontact tion 12. ECOLOGICAL IN pxicity ponents: lose: ity to fish	 Symptoms: Ey Symptoms: hy Remarks: May Based on Hum NFORMATION LC50 (Oryzias Exposure time Remarks: Base 	potension cause harm to the unborn child. han Evidence latipes (Japanese medaka)): > 100 mg/l : 48 h
Not cl Exper Comp Olme: Eye cl Ingest CTION Ecoto Comp Cellul Toxici	assified based on ava rience with human e <u>ponents:</u> sartan: ontact tion 12. ECOLOGICAL IN pxicity ponents: lose: ity to fish stence and degrada ponents:	 Symptoms: Ey Symptoms: hy Remarks: May Based on Hum NFORMATION LC50 (Oryzias Exposure time Remarks: Base 	potension cause harm to the unborn child. han Evidence latipes (Japanese medaka)): > 100 mg/ : 48 h



Olmesartan Formulation

Version 2.3	Revision Date: 10.10.2020		OS Number: 7985-00010	Date of last issue: 13.09.2019 Date of first issue: 01.06.2016
	ccumulative potential			
	ata available			
	lity in soil ata available			
	r adverse effects ata available			
SECTION	13. DISPOSAL CONS	SIDER	ATIONS	
Dispo	osal methods			
	e from residues aminated packaging	:	Empty contain handling site for	accordance with local regulations. ers should be taken to an approved waste or recycling or disposal. e specified: Dispose of as unused product.
SECTION	14. TRANSPORT INF	ORM		
	14. TRANSPORT INF	ORM		
Interr UNR1	national Regulations	-	ATION	
Interr UNR Not re IATA	national Regulations TDG egulated as a dangerou	us goo	ATION	

Not applicable for product as supplied.

Domestic regulation

NOM-002-SCT Not regulated as a dangerous good

Special precautions for user

Not applicable

SECTION 15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Federal Law for the control of chemical precursors, : Not applicable essential chemical products and machinery for producing capsules, tablets and pills.

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined



Olmesartan Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
2.3	10.10.2020	717985-00010	Date of first issue: 01.06.2016

SECTION 16. OTHER INFORMATION

Full text of other abbreviations

ACGIH NOM-010-STPS-2014	:	USA. ACGIH Threshold Limit Values (TLV) Mexico. Norm NOM-010-STPS-2014 on Chemicals Polluting the Work Environment - Identification, Assessment and Con-
		trol - Appendix 1 Occupational Exposure Limits
ACGIH / TWA	:	8-hour, time-weighted average
NOM-010-STPS-2014 / VLE-	:	Time weighted average limit value
PPT		

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Sources of key data used to compile the Material Safety Data Sheet	:	Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, http://echa.europa.eu/
Revision Date	:	10.10.2020



Olmesartan Formulation

Version	Revision Date:	SDS Number:
2.3	10.10.2020	717985-00010

Date of last issue: 13.09.2019 Date of first issue: 01.06.2016

The information is considered as correct, but not exhaustive, and will be used only as a guide, which is based in the current knowledge of the substance or mixture, and is applicable to proper safety precautions for the product.

MX / Z8